US90184D1000 - Common Stock
TWIST BIOSCIENCE CORP
NASDAQ:TWST (5/2/2024, 3:51:04 PM)
After market: 35 +2.99 (+9.34%)32.01
+0.05 (+0.16%)
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 919 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The firm leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. The company has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. The company offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. The company offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
TWIST BIOSCIENCE CORP
681 Gateway Blvd.
South San Francisco CALIFORNIA 94080
P: 18007190671
CEO: Emily M. Leproust
Employees: 919
Website: https://www.twistbioscience.com/
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future.
Here you can normally see the latest stock twits on TWST, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: